Condition (MeSH)
Transfusion Reaction
ClinicalTrials.gov lists 62 trials for Transfusion Reaction or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
55 of the 62 trials are tagged with Transfusion Reaction itself; the rest are tagged with a narrower condition beneath it.
When did Transfusion Reaction trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 7 |
| 2022 | 6 |
| 2021 | 3 |
| 2020 | 6 |
| 2019 | 8 |
| 2018 | 3 |
| 2017 | 5 |
| 2016 | 4 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 29 months across 33 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Transfusion Reaction trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 17 |
| Observational | 31 |
How many Transfusion Reaction trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 7 |
| Active, not recruiting | 1 |
| Completed | 31 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Transfusion Reaction trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Diagast | 3 |
| National Institutes of Health Clinical Center (CC) | 3 |
| Cerus Corporation | 2 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Blood Transfusion | 5 |
| Acute normovolemic hemodilution (ANH) | 2 |
| Transfusion | 2 |
| Standard RBCs | 1 |
| Furosemide-IR | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Transfusion Reaction trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hypernatremia associated with hypertonic saline use | 5 | 1 |
| Hyperkalemia | 2 | 1 |
| Profound Anemia | 2 | 1 |
| hypoxemia | 2 | 1 |
| Acute respiratory failure | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover Transfusion Reaction? (390)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Transfusions in autoimmune hemolytic anemias: Frequency and clinical significance of alloimmunization. | Journal of internal medicine | 2024 | Yes |
| Donor sex, pre-donation hemoglobin, and manufacturing affect CD71<sup>+</sup> cells in red cell concentrates. | Transfusion | 2023 | Yes |
| Immunological impact of the CD71<sup>+</sup> RBCs: A potential immune mediator in transfusion. | Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis | 2023 | Yes |
| Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia. | Blood advances | 2022 | Yes |
| The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial. | Trials | 2022 | Yes |
Showing 5 of 390 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.